Allvivo Vascular

Executive Summary

Allvivo Vascular is a private biomedical company headquartered in Lake Forest, California, specializing in antimicrobial coatings designed to prevent and eradicate infections associated with medical devices and wound care. Founded in 2003, the company leverages proprietary engineered antimicrobial peptides to create advanced formulations that disrupt biofilm formation and device-related infections. By targeting a critical unmet need in healthcare—simplifying infection control while improving patient outcomes and reducing costs—Allvivo’s technology has the potential to enhance the safety and performance of cardiovascular devices, catheters, surgical implants, and wound dressings. The company's platform is versatile and could be integrated into a wide range of medical products, offering a differentiated solution in the infection prevention market. As a private entity with no disclosed funding rounds or revenue, Allvivo Vascular operates with limited public visibility. However, its focus on antimicrobial resistance and hospital-acquired infections positions it favorably in a growing market driven by regulatory emphasis on infection control. Key challenges include the need for clinical validation, regulatory clearances, and commercial partnerships to scale its technology. If successful, Allvivo could become a key supplier of antimicrobial coatings for medical device manufacturers. The company’s long development cycle and capital requirements underscore the importance of strategic collaborations to reach commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for lead antimicrobial coating on a vascular graft40% success
• Q2 2027Strategic partnership with a major medical device OEM50% success
• Q3 2026Publication of preclinical efficacy data in a peer-reviewed journal70% success